ArticleFrontiers in oncology2025
Case Report: Relapsed alveolar rhabdomyosarcoma treated with abemaciclib, temozolomide, and irinotecan in the JPCS study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04238819 (A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclin-dependent kinase (CDK) 4 and CDK6 play fundamental roles in cell cycle progression. The CDK4/6 inhibitor abemaciclib, in combination with temozolomide and irinotecan, was evaluated in pediatric and young adult patients with relapsed/refractory solid tumors in the phase 1b dose-escalation study, JPCS Part A (NCT04238819). This case report describes the notable results of a patient with relapsed alveolar rhabdomyosarcoma (ARMS) who experienced a prolonged complete response. Case presentation: An 8-year-old White male was initially diagnosed with stage IV ARMS with Conclusion: CDK4/6 inhibition with abemaciclib in combination with temozolomide and irinotecan provided a durable response in a patient with heavily pretreated ARMS. Additional studies may be warranted to further understand the role of CDK4/6 inhibitors for treatment of ARMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.